



INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy.

Olivia Boyer, Fabien Nevo, Emmanuelle Plaisier, Benoît Funalot, Olivier Gribouval, Geneviève Benoit, Evelyne Huynh Cong, Christelle Arrondel, Marie-Josèphe Tête, Rodrick Montjean, et al.

► To cite this version:

Olivia Boyer, Fabien Nevo, Emmanuelle Plaisier, Benoît Funalot, Olivier Gribouval, et al.. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy.. New England Journal of Medicine, 2011, 365 (25), pp.2377-88. 10.1056/NEJMoa1109122 . inserm-00919173

HAL Id: inserm-00919173

<https://inserm.hal.science/inserm-00919173>

Submitted on 16 Dec 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ORIGINAL ARTICLE

INF2 Mutations in Charcot–Marie–Tooth Disease with Glomerulopathy

Olivia Boyer, M.D., Ph.D., Fabien Nevo, M.Sc., Emmanuelle Plaisier, M.D., Ph.D., Benoit Funalot, M.D., Ph.D., Olivier Gribouval, M.Sc., Geneviève Benoit, M.D., Evelyne Huynh Cong, M.Sc., Christelle Arrondel, M.Sc., Marie-Josèphe Tête, M.D., Rodrick Montjean, Ph.D., Laurence Richard, M.Sc., Alexandre Karras, M.D., Claire Pouteil-Noble, M.D., Ph.D., Leila Balafrej, M.D., Alain Bonnardeaux, M.D., Ph.D., Guillaume Canaud, M.D., Christophe Charasse, M.D., Jacques Dantal, M.D., Ph.D., Georges Deschenes, M.D., Ph.D., Patrice Deteix, M.D., Odile Dubourg, M.D., Ph.D., Philippe Petiot, M.D., Dominique Pouthier, M.D., Eric Leguern, M.D., Ph.D., Anne Guiochon-Mantel, M.D., Ph.D., Isabelle Broutin, Ph.D., Marie-Claire Gubler, M.D., Sophie Saunier, Ph.D., Pierre Ronco, M.D., Ph.D., Jean-Michel Vallat, M.D., Miguel Angel Alonso, Ph.D., Corinne Antignac, M.D., Ph.D., and Géraldine Mollet, Ph.D.

ABSTRACT

BACKGROUND

Charcot–Marie–Tooth neuropathy has been reported to be associated with renal diseases, mostly focal segmental glomerulosclerosis (FSGS). However, the common mechanisms underlying the neuropathy and FSGS remain unknown. Mutations in *INF2* were recently identified in patients with autosomal dominant FSGS. *INF2* encodes a formin protein that interacts with the Rho-GTPase CDC42 and myelin and lymphocyte protein (MAL) that are implicated in essential steps of myelination and myelin maintenance. We therefore hypothesized that *INF2* may be responsible for cases of Charcot–Marie–Tooth neuropathy associated with FSGS.

METHODS

We performed direct genotyping of *INF2* in 16 index patients with Charcot–Marie–Tooth neuropathy and FSGS who did not have a mutation in *PMP22* or *MPZ*, encoding peripheral myelin protein 22 and myelin protein zero, respectively. Histologic and functional studies were also conducted.

RESULTS

We identified nine new heterozygous mutations in 12 of the 16 index patients (75%), all located in exons 2 and 3, encoding the diaphanous-inhibitory domain of *INF2*. Patients presented with an intermediate form of Charcot–Marie–Tooth neuropathy as well as a glomerulopathy with FSGS on kidney biopsy. Immunohistochemical analysis revealed strong *INF2* expression in Schwann-cell cytoplasm and podocytes. Moreover, we demonstrated that *INF2* colocalizes and interacts with MAL in Schwann cells. The *INF2* mutants perturbed the *INF2*–MAL–CDC42 pathway, resulting in cytoskeleton disorganization, enhanced *INF2* binding to CDC42 and mislocalization of *INF2*, MAL, and CDC42.

CONCLUSIONS

INF2 mutations appear to cause many cases of FSGS-associated Charcot–Marie–Tooth neuropathy, showing that *INF2* is involved in a disease affecting both the kidney glomerulus and the peripheral nervous system. These findings provide new insights into the pathophysiological mechanisms linking formin proteins to podocyte and Schwann-cell function. (Funded by the Agence Nationale de la Recherche and others.)

The authors' affiliations are listed in the appendix. Address reprint requests to Dr. Antignac at INSERM U983, 6e étage, Tour Lavoisier, Hôpital Necker–Enfants Malades, 149 Rue de Sèvres, 75015 Paris, France, or at corinne.antignac@inserm.fr.

N Engl J Med 2011;365:2377–88.
Copyright © 2011 Massachusetts Medical Society.

CHARCOT–MARIE–TOOTH DISEASE REFERS to a heterogeneous group of inherited chronic peripheral motor and sensory neuropathies.¹ Affected persons typically present with progressive distal-muscle weakness and atrophy, reduced tendon reflexes, and foot and hand deformities. Three Charcot–Marie–Tooth disease subtypes have been distinguished by means of electrophysiological and neuropathological studies — a glial myelinopathy (type 1) characterized by slow motor-nerve conduction velocities and demyelinating neuropathy, an axonal form (type 2) associated with normal or subnormal nerve conduction velocities and axonal degeneration, and an intermediate form with demyelinating and axonal features in which patients from the same family may have either subnormal or reduced nerve conduction velocities.² At least 40 different genes or loci have been associated with this disease (as has been reviewed by Lupski and colleagues).³ Autosomal dominant Charcot–Marie–Tooth type 1 is the most prevalent form, with mutations in the peripheral myelin protein 22 gene (*PMP22*) and the myelin protein zero gene (*MPZ*) underlying most cases.^{4,5}

An increased prevalence of nephropathies, particularly focal segmental glomerulosclerosis (FSGS), has been documented in patients with Charcot–Marie–Tooth neuropathy,⁶ but the pathophysiological mechanism linking these two clinical entities is unknown. FSGS is a histologic pattern of renal damage that is associated with a spectrum of primary and secondary glomerular diseases, including isolated proteinuria and glucocorticoid-resistant nephrotic syndrome.⁷ In the past few years, the identification of genes involved in hereditary glomerulopathies has expanded knowledge about the crucial role of the podocyte, a glomerular epithelial cell with interdigitating foot processes, as well as its actin cytoskeleton, in the function of the glomerular filtration barrier.⁸

INF2 mutations account for 12 to 17% of autosomal dominant cases of FSGS.^{9,10} The gene encodes a member of the diaphanous-related formin family, which is involved in remodeling the actin and microtubule cytoskeletons.¹¹ *INF2* possesses functional domains characteristic of other diaphanous-related formins: an N-terminal diaphanous-inhibitory domain (DID), the formin homology domains FH1 and FH2, and a C-terminal diaphanous-autoregulatory domain (DAD).¹¹ However, *INF2* has a unique ability to promote not only actin polymerization but also filament severing and depolymerization.¹²

INF2 interacts with other diaphanous-related formins, such as mDia1–DIAPH1¹³ and the Rho-GTPase CDC42,^{14,15} through its DID. In addition, it has been shown to bind (through its C-terminal) the myelin and lymphocyte protein (MAL) in Jurkat T cells¹⁵ and MAL2 in Madin–Darby canine kidney cells and HepG2 hepatocytes¹⁴ to regulate intracellular protein transport.^{14–16} Although very little is known about the role of diaphanous-related formins in the peripheral nervous system, the implication of CDC42¹⁷ and MAL¹⁸ in essential steps of myelination and myelin maintenance led us to hypothesize that *INF2* mutations may be responsible for the association between FSGS and Charcot–Marie–Tooth neuropathy.

METHODS

STUDY PARTICIPANTS


The study was conducted from March 2010 through September 2011. Sixteen index patients (seven with apparent autosomal dominant inheritance and nine with sporadic disease) from 16 unrelated families were included in the study. Twelve were from our French FSGS DNA cohort, including 2 families described previously.^{19,20} We contacted authors of published cases of FSGS and Charcot–Marie–Tooth neuropathy^{6,21} and thereby obtained DNA samples from 4 additional families. Twenty-five members of the patients' families were also tested. All index patients presented with clinical manifestations of Charcot–Marie–Tooth disease associated with FSGS. The index patients had all been diagnosed with Charcot–Marie–Tooth disease by a neurologist in their primary care centers on the basis of their clinical history, physical examination, and electrophysiological or histologic testing. Mutations in *PMP22* or *MPZ* were ruled out in all patients. Written informed consent was obtained from all study participants or their parents, and the study was approved by the Comité de Protection des Personnes Ile-De-France II.

GENETIC, HISTOLOGIC, AND FUNCTIONAL STUDIES

INF2 exons 2, 3, and 4 were sequenced for all participants, and in the absence of mutations, the remaining exons were sequenced (as previously described¹⁰). Localization of *INF2*, MAL, and MAL2 in normal human kidney and peripheral-nerve specimens and in cultured Schwann cells was assessed by means of immunoperoxidase and immunofluorescence staining. The interaction of *INF2* with MAL in Schwann cells was demonstrated by

Figure 1. Summary of INF2 Substitutions in the 12 Study Patients.

Panel A shows substitutions identified in the study patients (red, in Panels A and B) as well as those found in previous studies of focal segmental glomerulosclerosis (FSGS) alone (green, in Panels A and B), aligned with the C-terminal sequence (indicated with the string of single-letter amino acid symbols) of human, mouse, and xenopus INF2 proteins, opossum INF2-like protein, and human and mouse DIAPH1 proteins. Residues important for the DID–DAD interaction²² are shown in blue or, if the residues were also altered in a patient presenting with FSGS and Charcot–Marie–Tooth neuropathy, in purple (in Panels A and B). The numbering of amino acids from the translation initiation site is shown to the right of each sequence, and armadillo repeats are shown to highlight the distinct localization of mutants associated with FSGS and Charcot–Marie–Tooth neuropathy and of mutants associated with FSGS alone. Panel B is a three-dimensional representation of the N-terminal portion of human INF2 viewed from opposing directions, constructed on the basis of the structure of mDial. The residues associated with FSGS and Charcot–Marie–Tooth neuropathy (red and purple) are located in the inner face of the central core of the DID, whereas the mutant residues responsible for FSGS only (green) are more externally located.



pull-down assay. The effects of INF2 mutant expression on interaction with active CDC42 and IQGAP1 were evaluated by coimmunoprecipitation, and the effects of INF2 mutant expression on intracellular localization of MAL and CDC42 and on the actin cytoskeleton were evaluated by immunofluorescence. Two INF2 mutants associated with FSGS and Charcot–Marie–Tooth neuropathy and three INF2 mutants associated with FSGS were studied. A detailed description of the methods used is provided in the Supplementary Appendix, available with the full text of the article at NEJM.org.

RESULTS

INF2 MUTATIONS

Heterozygous *INF2* mutations were detected in 12 of the 16 index patients (75%). Nine different mutations were identified: eight missense mutations and one in-frame deletion of three amino acids. All were new mutations located in exons 2 and 3, which encode the DID domain (Fig. 1A, and Table 1S in the Supplementary Appendix), and all caused nonconservative changes in highly conserved amino acids. Scores from PolyPhen-2 software analysis ([pph2\) to predict the functional effects of missense *INF2* variants ranged from 0.993 to 1, predicting that *INF2* variants were probably damaging. No *INF2* variants were present in any of the 670 control chromosomes assayed or referenced in the National Heart, Lung, and Blood Institute's](http://genetics.bwh.harvard.edu/</p>
</div>
<div data-bbox=)

Exome Sequencing Project server. Mutations segregated with the disease in each familial case, although intrafamilial variability was noted (Fig. 1S in the Supplementary Appendix). A *de novo* mutation was confirmed in all three sporadic cases for which DNA was available from both parents of the patient. Most mutations identified in patients exhibiting FSGS and Charcot-Marie-Tooth neuropathy were localized in the 3' end of exon 2 and in exon 3, in which no mutation has been identified to date (to our knowledge). The *INF2* variants were clustered between nucleotides 300 and 500, whereas most isolated FSGS mutants were located downstream of nucleotide 500. To make functional predictions, we mapped mutants associated with FSGS alone^{9,10} and those associated with FSGS and Charcot-Marie-Tooth neuropathy onto a human *INF2* DID in silico model (Fig. 1B); although all involved DID residues, mutations in the two groups of patients were distinctly localized, the latter being located mostly in the second and third DID armadillo repeats and the former mostly in the fourth armadillo repeat (Fig. 1B).

To evaluate the potential role of *INF2* in isolated Charcot-Marie-Tooth disease, we performed mutational analysis of *INF2* exons 2, 3, and 4 in an additional group of 50 patients who presented with Charcot-Marie-Tooth disease without a known renal phenotype, nerve conduction velocities in the intermediate range (25 to 45 m per second),² and without any *PMP22* duplication or deletion or *MPZ* mutation. No pathogenic mutation was identified in this group.

PHENOTYPE OF PATIENTS WITH *INF2* MUTATIONS

The 12 index patients with *INF2* mutations presented with proteinuria at a median age of 18 years (range, 10 to 21), and end-stage renal disease (ESRD) developed in 11 patients at a median age of 21 years (range, 12 to 47) (Table 1). All patients exhibited lesions of FSGS (not otherwise specified)⁷ (Fig. 2A), but full-blown nephrotic syndrome was noted in only 5.

The neurologic phenotype of index cases is detailed in Table 1 and in the Supplementary Appendix. The median age at onset of peripheral-nerve dysfunction was 13 years (range, 5 to 28). Ten of the 12 index patients had moderate to severe symptoms at diagnosis, including walking difficulties and limited hand function, muscle wasting, and abolition of deep tendon reflexes in the lower and

upper limbs. Four patients also had mild or moderate sensorineural hearing loss. In addition, magnetic resonance imaging of the brain, performed in 2 patients (15 and 48 years old), showed central nervous system anomalies characterized by white-matter hyperintensity and ventricular dilation, which were more severe in the older patient (Fig. 2B). Median-nerve conduction velocities were in the range of intermediate Charcot-Marie-Tooth neuropathy (23 to 45 m per second). Patient K.3 had almost normal median-nerve conduction velocities (45 m per second), whereas her maternal aunt had reduced velocities (30 m per second; data not shown). The six available sural-nerve biopsy specimens all showed a pattern of lesions with a combination of axonal and demyelinating changes, characterized by a marked decrease in myelinated fibers (Fig. 2C), as compared with that in age-matched controls, and numerous multilayered "onion bulbs" (Fig. 2D). Together, these data suggest an intermediate Charcot-Marie-Tooth phenotype in patients with *INF2* mutations.

INF2 EXPRESSION IN PODOCYTES AND SCHWANN CELLS

In peripheral nerves, we detected robust *INF2* staining in Schwann cells and lighter staining in some axons (Fig. 3A, and Fig. 2S in the Supplementary Appendix). In the kidney, we confirmed that *INF2* expression occurs predominantly in podocytes. We detected weak staining in the proximal and distal tubules and found no *INF2* in vessels. In kidney-tissue and sural-nerve sections from the patients, *INF2* staining persisted, but the severity of the lesions precluded our drawing any conclusion with respect to putative overexpression.

INF2 AND MAL IN SCHWANN CELLS


MAL interacts with *INF2*¹⁵ and is a major component of myelin.¹⁸ We therefore hypothesized that mutant *INF2* proteins could alter the *INF2*-MAL pathway in Schwann cells. We demonstrated the presence of *INF2*, together with MAL, in normal human peripheral-nerve serial sections and the endogenous colocalization of *INF2* and MAL in mouse Schwann cells (Fig. 3A and 3B). Moreover, glutathione S-transferase-pull-down experiments revealed an interaction between the *INF2* C-terminal and endogenous MAL in Schwann cells (Fig. 3C). We also confirmed *INF2* and MAL2 localization in human podocytes, and the absence of MAL in the glomeruli (Fig. 3A).

Table 1. Neurologic and Renal Phenotype of the 12 Index Patients with *INF2* Mutations.

Index Patient	Age at Proteinuria Onset	Time of Biopsy				Age at ESRD Onset	Age at Onset of Peripheral-Nerve Dysfunction	Muscle Weakness	Sural-Nerve Histologic Characteristics	Sensorineural Hearing Loss	Brain MRI Anomaly	Nerve Conduction Velocity	
		Age	Urine Protein	Plasma Albumin	Plasma Creatinine							ESP Nerve	Median Nerve
		yr	g/liter	g/dl	mg/dl							yr	m/sec
A.3	10	13	1.0	3.9	0.6	20	10	Severe	No axons, numerous onion bulbs	Yes	Yes	No potential	No potential
B.4	12	12	1.8	4.0	5.4	12	6	Severe	ND	No	ND	No potential	No potential
C.1	11	15	9.0	2.4	13.6	15	12	Moderate	Axonal loss, numerous onion bulbs	No	Yes	No potential	No potential
D.1†	19	21	1.5–3.0	3.0	0.9	26	8	Severe	ND	No	ND	<30	<30
E.2	18	Unknown	Unknown	Unknown	Unknown	18	24	Severe	Axonal loss, few onion bulbs	Yes	ND	No potential	32
F.3	14	17	9.3	2.3	1.0	23	5	Severe	Severe axonal loss, numerous onion bulbs	No	ND	No potential	23
G.1	14	14	>3.0	<3.0	Normal	22	5	Severe	ND	Yes	ND	No potential	No potential
H.1	19	21	8.5	3.3	0.8	29	20	Severe	Axonal loss, numerous onion bulbs	No	ND	No potential	42
I.1	21	21	2.8	4.3	10.2	21	10	Moderate	Axonal loss, numerous onion bulbs	No	ND	No potential	30–32
J.3	21	27	7.5	3.4	1.9	No ESRD to date (at 32 yr)	28	Mild	ND	Yes	ND	ND (patient declined)	
K.3	20	20	4.0	Unknown	16.6	20	20	Severe	ND	No	ND	15–28	45
L.1	20	27	Unknown	Unknown	Unknown	47	20	Mild	ND	No	ND	No potential	41–42

* To convert the values for creatinine to micromoles per liter, multiply by 88.4. ESP denotes external sciatic popliteal, ESRD end-stage renal disease, MRI magnetic resonance imaging, and ND not done.

† This family has been previously described by Lemieux and Neemeh.²¹



We then investigated the effects of INF2 mutants on MAL localization (Fig. 3D). In contrast to the perinuclear localization of the wild-type form of INF2,^{9,25} INF2 mutants in patients with FSGS and Charcot-Marie-Tooth disease were diffusely localized throughout the cytoplasm, similar to the FSGS mutants studied here and by others.⁹ We also observed that MAL had a perinuclear localization when transfected alone or with the wild-type form of INF2, whereas its distribution

was diffuse throughout the cell with INF2 mutants, and that the two proteins were colocalized (Fig. 3C). Costaining of endogenous protein disulfide isomerase (PDI) confirmed the predominant localization of wild-type INF2 to the endoplasmic reticulum.²⁵ In cells expressing INF2 mutants, the mislocalization of INF2 coincided with a diffuse pattern of PDI staining, which could reflect cytoskeleton disorganization (Fig. 3S in the Supplementary Appendix).

INF2 MUTANTS AND ACTIN CYTOSKELETON REGULATION

Cells expressing mutant INF2 exhibited less cortical actin and a reduced number of long actin stress fibers than those expressing wild-type INF2, and a disorganized microtubule network (Fig. 4S, 5S, and 6S in the Supplementary Appendix). Similar features were observed with the K/A–3L/A–INF2 mutant that lacks both the polymerization and depolymerization activities of wild-type INF2,¹⁴ although with this mutant the decrease in the content of long actin filaments was less severe.

We therefore investigated whether the mutations in INF2 proteins affect their binding to CDC42, an actin-regulating Rho-GTPase known to interact, in its GTP-loaded active state, with the INF2 DID.¹⁴ An enhanced interaction was observed between the INF2 mutants and a constitutively active form of CDC42 (CDC42-Q61L) as compared with the wild-type INF2 protein (Fig. 4A and 4B). Moreover, INF2 mutants affected the subcellular localization of CDC42-Q61L, with the fraction of active CDC42 at the plasma membrane being lost in a large proportion of mutant cells as compared with cells expressing wild-type INF2 (Fig. 4C), but did not significantly perturb CDC42 activity (Fig. 7S in the Supplementary Appendix), a result consistent with INF2 being a downstream target of CDC42.^{14,15} We also demonstrated the interaction of INF2 with IQGAP1, a CDC42 effector known to interact with mDia1.^{26,27} INF2 mutants still interacted with IQGAP1 and altered the endogenous IQGAP1 subcellular distribution (Fig. 8S in the Supplementary Appendix), as they did for MAL and CDC42.

DISCUSSION

We have demonstrated that, in addition to leading to isolated FSGS, *INF2* mutations are a major cause of Charcot–Marie–Tooth disease associated with FSGS, accounting for approximately 75% of all cases. These results shed new light on the genetic basis of the dual neurologic and renal phenotype first described by Lemieux and Neemeh in 1967.²¹

Since the initial description, several cases of renal involvement (mostly glomerular disorders with FSGS lesions) have been reported in association with Charcot–Marie–Tooth disease.⁶ Plaisier and colleagues²⁸ demonstrated the presence of myelin protein zero (MPZ) in podocytes and an increased urinary albumin excretion in *Mpz* knock-

out mice, indicating a potential role of myelin components in glomerular permselectivity. No *PMP22* or *MPZ* mutation has been reported in patients with FSGS and Charcot–Marie–Tooth neuropathy. In contrast, three quarters of the patients in the present study had *INF2* mutations. None of these mutations were present in patients with Charcot–Marie–Tooth disease only, suggesting that *INF2* is not involved in cases of the disease without an apparent renal phenotype. Nevertheless, because of the individual and intrafamilial phenotypic variability we observed, physicians should be alert for proteinuria in all patients who have Charcot–Marie–Tooth disease. Similarly, pes cavus was the only clinical sign of Charcot–Marie–Tooth disease in some members of patients' families; therefore, a careful clinical neurologic evaluation should be considered for patients with FSGS.

Although *INF2* mutations have been shown to be the major cause of autosomal dominant isolated FSGS, accounting for 12 to 17% of all cases,^{9,10} the prevalence of *INF2* mutations in association with FSGS and Charcot–Marie–Tooth disease is much higher (75%). Several lines of genetic and functional evidence indicate that these variants are pathogenic mutations. Given the high prevalence of *INF2* mutations, the detection of various distinct *INF2* mutations, and the absence of mutations in *PMP22* and *MPZ*, the occurrence of a mutation in another gene underlying Charcot–Marie–Tooth disease in patients with *INF2*-related FSGS is unlikely. Moreover, it is improbable that the frequent de novo mutations we detected would occur in two distinct genes in the same patient. Furthermore, all of the nine *INF2* mutations we identified are new. Although the nine mutations encode DID residues, as do mutations associated with isolated FSGS, they had a distinct localization, corresponding mostly to the 3' end of exon 2 as well as in exon 3, in which no isolated FSGS mutation has been identified.

We further explored the functional effects of some *INF2* mutations. We postulated that the mechanisms linking *INF2* to the development of Charcot–Marie–Tooth disease involved perturbation of cytoskeletal networks and thus intracellular transport of myelin components. Indeed, *INF2* has been shown to regulate specialized routes of protein targeting to the plasma membrane in various types of cells in association with CDC42 and MAL or MAL2.^{14,15} This targeting involves vesicular carriers that associate with actin filaments and re-

quires both the actin polymerization and depolymerization properties of INF2.^{14,15} In addition, CDC42 and MAL are fundamental players in peripheral myelination.^{17,18,29} Here we show that INF2 is also expressed in Schwann cells and to a lesser extent in neurons. We also demonstrate the endogenous colocalization of INF2 and MAL and their *in vivo* interaction in Schwann cells, thereby providing a clear rationale for the role of *INF2* mutations in Charcot–Marie–Tooth disease. In addition, we show that *INF2* mutations disrupt the INF2–MAL–CDC42 pathway. The reduction in cortical actin and stress fibers in cells expressing INF2 DID mutants was even more severe than in cells expressing the K/A–3L/A–INF2 mutant lacking both the polymerization and depolymerization properties of INF2. This suggests that INF2 DID mutants might not only alter these two functions but also have additional effects on INF2 partners. Indeed, we demonstrated an enhanced interaction between the INF2 DID mutants and CDC42 and a reduced fraction of active CDC42 at the plasma membrane. Together, our results suggest that the mislocalization of the INF2–MAL–CDC42 complex in the cytoplasm, as well as the defects in the polymerization and depolymerization activities of INF2 required for actin dynamics, could disrupt protein targeting to the plasma membrane and therefore also disrupt proper myelin formation and maintenance.

The implication of the Rho-GTPase CDC42 pathway in the effect of the *INF2* mutants is reminiscent of mutations in two genes involved in dominant intermediate Charcot–Marie–Tooth disease: *DNM2*, which encodes the GTPase protein dynamin 2,³⁰ and *ARHGEF10*, which encodes a guanine exchange factor that activates Rho-GTPases.³¹


Finally, sensorineural hearing loss was present in 4 of the 12 families (33%) with an *INF2* mutation, which is a prevalence significantly higher than the approximately 5% prevalence reported among patients with Charcot–Marie–Tooth disease.³² Mutations in *DIAPH1*, which encodes mDia1, have been associated with autosomal dominant sensorineural progressive hearing loss.³³ The biologic role of mDia1 in hearing is likely to include regulation of actin polymerization in hair cells of the inner ear. Sun and colleagues¹³ recently demonstrated that the INF2 DID interacts with the mDia1 DAD. Thus, similar mechanisms

Figure 3 (facing page). Colocalization and Interaction of Wild-Type and Mutant INF2 with Myelin and Lymphocyte Protein (MAL).

Panel A (immunoperoxidase stain) shows MAL, INF2, and MAL2 proteins in normal human kidney specimens and peripheral-nerve biopsy specimens. The serial sections shown suggest that INF2 colocalizes with MAL2 in podocytes and MAL in Schwann cells. Panel B shows immunostaining of endogenous INF2 (green) and MAL (red) in MSC-80 mouse Schwann cells (with the merged image also shown).²³ The scatter plot represents red and green pixel fluorescence intensities of the corresponding immunostaining. Both proteins were colocalized (for eight samples analyzed: median Pearson's coefficient, 0.909; range, 0.625 to 0.978).²⁴ Panel C shows results of an INF2–MAL pull-down assay performed on the detergent-insoluble (I) membrane fraction of S16 rat Schwann cells separated from the soluble fraction (S) and the Ponceau red staining of the glutathione *S*-transferase proteins used at the bottom. In Schwann cells, endogenous MAL bound the C-terminal of INF2. Panel D shows the colabeling of wild-type or mutant FLAG-tagged INF2 (red) with myelocytomatosis virus–associated sequence (MYC)–tagged MAL (green) transiently expressed in HeLa cells, with the corresponding scatter plot of red and green pixel fluorescence intensities on the right. In contrast to the perinuclear localization of wild-type INF2, the two INF2 mutants (with amino acid change L165P or R106P) in patients with focal segmental glomerulosclerosis (FSGS) and Charcot–Marie–Tooth (CMT) neuropathy were spread throughout the cytoplasm. As observed with endogenous proteins, wild-type INF2 and MAL recombinant proteins were colocalized (see merged images). For INF2 mutants, the colocalization persisted, leading to a broader cytoplasmic distribution of MAL.

are likely to be involved in deafness related to either *DIAPH1* or *INF2* mutations.

The reasons why *INF2* mutations do not always lead to a neurologic phenotype still need to be clarified. One clue, however, is that the mutations underlying FSGS alone or in combination with Charcot–Marie–Tooth neuropathy are clustered in different parts of the DID. The latter mutations are located between two putative DID-binding pockets, suggesting that they could affect DID function more severely than mutations related to FSGS alone, by simultaneously disrupting the interaction of INF2 with multiple proteins, some of which could be specific myelin proteins. This is consistent with the renal phenotype that is more severe in patients with FSGS and Charcot–Marie–Tooth disease than in patients with FSGS (median age at






Figure 4 (facing page). Effects of Disease-Causing *INF2* Mutations on the *INF2*–*CDC42* Interaction and *CDC42* Subcellular Localization.

Panel A shows the *in vivo* interaction of the constitutively active form of *CDC42* (human influenza hemagglutinin [HA]–*CDC42*–Q61L) and FLAG-tagged wild-type and mutant *INF2* constructs in HEK-293T cells. The histogram shows the amount of co-immunoprecipitated *INF2* protein normalized to the amount of immunoprecipitated *CDC42* protein. The ratio of wild-type FLAG-*INF2* to HA-*CDC42*–Q61L was set to 1, and all other values were calculated relative to it. Panel B shows HeLa cells transfected with plasmids encoding either a wild-type or mutant FLAG-tagged *INF2* (red) and a constitutively active HA-tagged form of *CDC42* (green). All cells expressing *CDC42*–Q61L alone or with wild-type *INF2* exhibited cytoplasmic staining of *CDC42*, and about 60% also showed membrane localization. Mutant forms of *INF2* led to a mislocalization of both proteins, the *INF2* staining being diffuse in the cytoplasm and *CDC42* being less targeted to the plasma membrane. The associated histogram represents the mean percentage of cells showing membrane staining of *CDC42* (with >30 cells cotransfected per experiment). CMT denotes Charcot–Marie–Tooth disease, and FSGS focal segmental glomerulosclerosis. T bars indicate the standard errors for three independent experiments. IP denotes immunoprecipitation.

min *INF2* as a crucial molecular entity in the occurrence of FSGS and Charcot–Marie–Tooth neuropathy provides additional insight into the role of similar cellular machinery in podocytes and Schwann cells, even though these two highly specialized cell types have distinct functions.

Supported by grants from the Association pour l'Utilisation du Rein Artificiel (to Dr. Antignac), Association Française contre les Myopathies (ANR-08-GENOPAT-017-01, to Dr. Antignac), Agence Nationale de la Recherche (PodoNet project number ANR-07-E-RARE-011-01 in the ERA-Net Consortium [JTC2007], to Dr. Antignac, and ANR-06-MRAR-024-01, to Dr. Leguern), Fondation pour la Recherche Médicale (project number DMP 2010-11-20-386, to Dr. Antignac, and doctoral funding, to Dr. Boyer), Association des Malades du Syndrome Néphrotique (to Dr. Mollet), Fonds de la Recherche en Santé du Québec (Fellowship Training Award to Dr. Benoit), and Ministerio de Ciencia e Innovación (BFU2009-07886 and CONSOLIDER COAT CSD2009-00016, to Dr. Alonso).

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Scott J. Harvey for helpful discussions; Martin R. Pollak, Philippe Chavrier, and Christopher Carpenter for providing FLAG-*INF2*–WT, GFP-IQGAP1–WT, and HA-*CDC42*–Q61L plasmids, respectively; Bernard Zalc for providing MSC-80 cells; Olivier Dorseuil for providing the GST-PAK construct; Catherine Lacroix, Laure-Hélène Noël, and Dominique Nochy for providing histologic sections; Nicolas Goudin (of Plateau d'Imagerie Cellulaire, Institut Fédératif de Recherche Necker–Enfants Malades, Paris) for providing expert knowledge on confocal microscopy; Drs. Bommelaer, Clavelou, Campone, Quélin, Rieu, Rouhart, Sarret, and Squalli Houssaini for providing medical information about their patients and the families who participated in this study; and the NHLBI Exome Sequencing Project (<http://snp.gs.washington.edu/EVS/>) for providing exome variant cells for comparison.

onset of proteinuria, 18 vs. 27 years, and of end-stage renal disease, 21 vs. 36 years),¹⁰ although this needs to be verified in a larger cohort.

In conclusion, the identification of the for-

APPENDIX

The authors' affiliations are as follows: INSERM Unité 983 (O.B., F.N., O.G., G.B., E.H.C., C. Arrondel, M.-J.T., R.M., M.-C.G., S.S., C. Antignac, G.M.), Unité 702 (E.P., P.R.), and Unité 975 (E.L.); Service de Néphrologie Pédiatrique (O.B.), Service de Transplantation et Soins Intensifs (G.C.), and Service de Génétique (C. Antignac), Hôpital Necker–Enfants Malades, Assistance Publique–Hôpitaux de Paris (AP-HP); Service de Néphrologie et Dialyses (E.P., P.R.), Hôpital Tenon, AP-HP; Service de Néphrologie (A.K.), Hôpital Européen Georges Pompidou, AP-HP; Service de Néphrologie Pédiatrique (G.D.), Hôpital Robert Debré, AP-HP; Institut de Myologie (O.D.), Hôpital Pitié–Salpêtrière, AP-HP; Université Paris Descartes, Sorbonne Paris Cité (O.B., F.N., O.G., E.H.C., C. Arrondel, M.-J.T., R.M., A.K., G.C., I.B., M.-C.G., S.S., C. Antignac, G.M.); Université Pierre et Marie Curie (E.P., E.L., P.R.); Université Paris Diderot (G.D.); Centre National de la Recherche Scientifique Unité 7225 (E.L.) and Laboratoire de Cristallographie et RMN Biologiques (I.B.) — all in Paris; Laboratoire et Service de Neurologie, Centre Hospitalier Universitaire (CHU) et Université de Limoges, Limoges (B.F., L.R., J.-M.V.); Université de Lyon (C.P.-N.), Service de Néphrologie, Centre Hospitalier Lyon-Sud (C.P.-N.), and Service de Neurologie, Hôpital de la Croix-Rousse (P.P.), Hospices Civils de Lyon — all in Lyon; Centre Hospitalier de Saint-Brieuc, Saint-Brieuc (C.C.); Service de Néphrologie et Immunologie Clinique, CHU Hôtel Dieu, Nantes (J.D.); CHU Gabriel Montpied, Université d'Auvergne, Clermont-Ferrand (P.D.); Génétique Moléculaire, Pharmacogénétique et Hormonologie, CHU Bicêtre, Université Paris-Sud, Le Kremlin-Bicêtre (A.G.-M.) — all in France; Service de Néphrologie Pédiatrique, CHU Sainte-Justine, Université de Montréal (G.B.); and Centre de Recherche Guy-Bernier, Hôpital Maisonneuve–Rosemont (A.B.) — both in Montreal; Centre de Néphrologie et d'Hémodialyse Riad, Rabat, Morocco (L.B.); Service de Néphrologie, Centre Hospitalier de Luxembourg, Luxembourg (D.P.); and Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas–Universidad Autónoma de Madrid, Madrid (M.A.A.).

REFERENCES

- Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. *Clin Genet* 1974;6:98-118.
- Pareyson D, Scaiola V, Laurà M. Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. *Neuromolecular Med* 2006;8:3-22.
- Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. *N Engl J Med* 2010;362:1181-91.

4. Patel PI, Roa BB, Welcher AA, et al. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. *Nat Genet* 1992;1:159-65.
5. Hayasaka K, Takada G, Ionasescu VV. Mutation of the myelin P0 gene in Charcot-Marie-Tooth neuropathy type 1B. *Hum Mol Genet* 1993;2:1369-72.
6. Paul MD, Fernandez D, Pryse-Phillips W, Gault MH. Charcot-Marie-Tooth disease and nephropathy in a mother and daughter with a review of the literature. *Nephron* 1990;54:80-5.
7. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. *Semin Nephrol* 2003;23:117-34.
8. Machuca E, Benoit G, Antignac C. Genetics of nephrotic syndrome: connecting molecular genetics to podocyte physiology. *Hum Mol Genet* 2009;18:R185-R194.
9. Brown EJ, Schlöndorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. *Nat Genet* 2010;42:72-6.
10. Boyer O, Benoit G, Gribouval O, et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. *J Am Soc Nephrol* 2011;22:239-45.
11. Chesarone MA, DuPage AG, Goode BL. Unleashing formins to remodel the actin and microtubule cytoskeletons. *Nat Rev Mol Cell Biol* 2010;11:62-74.
12. Chhabra ES, Higgs HN. INF2 is a WASP homology 2 motif-containing formin that severs actin filaments and accelerates both polymerization and depolymerization. *J Biol Chem* 2006;281:26754-67.
13. Sun H, Schlöndorff JS, Brown EJ, Higgs HN, Pollak MR. Rho activation of mDia formins is modulated by an interaction with inverted formin 2 (INF2). *Proc Natl Acad Sci U S A* 2011;108:2933-8.
14. Madrid R, Aranda JF, Rodríguez-Fratcelli AE, et al. The formin INF2 regulates basolateral-to-apical transcytosis and lumen formation in association with Cdc42 and MAL2. *Dev Cell* 2010;18:814-27.
15. Andrés-Delgado L, Antón OM, Madrid R, Byrne JA, Alonso MA. Formin INF2 regulates MAL-mediated transport of Lck to the plasma membrane of human T lymphocytes. *Blood* 2010;116:5919-29.
16. Marazuela M, Alonso MA. Expression of MAL and MAL2, two elements of the protein machinery for raft-mediated transport, in normal and neoplastic human tissue. *Histol Histopathol* 2004;19:925-33.
17. Benninger Y, Thurnherr T, Pereira JA, et al. Essential and distinct roles for cdc42 and rac1 in the regulation of Schwann cell biology during peripheral nervous system development. *J Cell Biol* 2007;177:1051-61.
18. Frank M. MAL, a proteolipid in glycosphingolipid enriched domains: functional implications in myelin and beyond. *Prog Neurobiol* 2000;60:531-44.
19. Deniau F, Guillot M, Plus A, et al. Charcot-Marie-Tooth disease and glomerular nephropathy. *Arch Fr Pediatr* 1986;43:791-3. (In French.)
20. Fillod I, Cochat P, Colon S, Wright C, David L. Nephropathy and Charcot-Marie-Tooth disease: a case report. *Pediatrics* 1990;45:319-22. (In French.)
21. Lemieux G, Neemeh JA. Charcot-Marie-Tooth disease and nephritis. *Can Med Assoc J* 1967;97:1193-8.
22. Rose R, Weyand M, Lammers M, Ishizaki T, Ahmadian MR, Wittinghofer A. Structural and mechanistic insights into the interaction between Rho and mammalian Dia. *Nature* 2005;435:513-8.
23. Boutry JM, Hauw JJ, Gansmüller A, Di-Bert N, Pouchelet M, Baron-Van Evercooren A. Establishment and characterization of a mouse Schwann cell line which produces myelin in vivo. *J Neurosci Res* 1992;32:15-26.
24. Bolte S, Cordelières FP. A guided tour into subcellular colocalization analysis in light microscopy. *J Microsc* 2006;224:213-32.
25. Chhabra ES, Ramabhadran V, Gerber SA, Higgs HN. INF2 is an endoplasmic reticulum-associated formin protein. *J Cell Sci* 2009;122:1430-40.
26. Bashour AM, Fullerton AT, Hart MJ, Bloom GS. IQGAP1, a Rac- and Cdc42-binding protein, directly binds and cross-links microfilaments. *J Cell Biol* 1997;137:1555-66.
27. Brandt DT, Marion S, Griffiths G, Watanabe T, Kaibuchi K, Grosse R. Dia1 and IQGAP1 interact in cell migration and phagocytic cup formation. *J Cell Biol* 2007;178:193-200.
28. Plaisier E, Mougnot B, Verpont MC, et al. Glomerular permeability is altered by loss of P0, a myelin protein expressed in glomerular epithelial cells. *J Am Soc Nephrol* 2005;16:3350-6.
29. Frank M, van der Haar ME, Schaeren-Wiemers N, Schwab ME. rMAL is a glycosphingolipid-associated protein of myelin and apical membranes of epithelial cells in kidney and stomach. *J Neurosci* 1998;18:4901-13.
30. Schafer DA, Weed SA, Binns D, Karginov AV, Parsons JT, Cooper JA. Dynamin2 and cortactin regulate actin assembly and filament organization. *Curr Biol* 2002;12:1852-7.
31. Verhoeven K, De Jonghe P, Van de Putte T, et al. Slowed conduction and thin myelination of peripheral nerves associated with mutant rho guanine-nucleotide exchange factor 10. *Am J Hum Genet* 2003;73:926-32.
32. Szigeti K, Lupski JR. Charcot-Marie-Tooth disease. *Eur J Hum Genet* 2009;17:703-10.
33. Lynch ED, Lee MK, Morrow JE, Welch PL, León PE, King MC. Nonsyndromic deafness DFNA1 associated with mutation of a human homolog of the *Drosophila* gene diaphanous. *Science* 1997;278:1315-8.

Copyright © 2011 Massachusetts Medical Society.

CLINICAL TRIAL REGISTRATION

The *Journal* requires investigators to register their clinical trials in a public trials registry. The members of the International Committee of Medical Journal Editors (ICMJE) will consider most reports of clinical trials for publication only if the trials have been registered. Current information on requirements and appropriate registries is available at www.icmje.org/faq_clinical.html.